Nootropics
Selegiline
A monoamine oxidase inhibitor with formulation-specific medical evidence; the US transdermal product is labeled for adult major depression.
Randomized depression trials and US transdermal label
Also known as: EMSAM
Practical use
Reviewed practical notes
- Identify the formulation
- Do not transfer patch evidence or precautions to every selegiline product.
- Review interactions comprehensively
- Include psychiatric medicines, pain medicines and nonprescription products in the clinical review.
- Keep expectations clinical
- Depression-trial findings do not demonstrate healthy cognitive enhancement.
2002 randomized transdermal trial
Overview
Selegiline inhibits monoamine oxidase. Its delivery system changes how the medicine acts and how its precautions apply. The studies summarized here concern a transdermal system for major depressive disorder, not a general-purpose cognitive supplement.
Risks and limitations
The US EMSAM label carries an antidepressant warning about suicidal thoughts and behavior in younger people and identifies serious interaction risks, including serotonin syndrome and hypertensive reactions. Application-site reactions are common. Dietary precautions depend on the prescribed treatment conditions and must follow the actual label.
How to read this
A trial conducted with a particular patch and participant group cannot establish that another formulation has identical effects or restrictions. The reviewed depression findings do not establish improved memory, motivation or healthy aging in people without the studied condition.
Research explained
Six-week transdermal trial
Who was studied
177 adult outpatients with major depressive disorder in a randomized placebo-controlled study.
What was found
Several depression symptom measures favored the active patch. Local skin reactions were a prominent adverse effect.
What it cannot establish
The study was short and involved a defined clinical population. Participants followed dietary restrictions, so its safety findings cannot simply be generalized to other treatment conditions.
Read the original studyEight-week transdermal trial
Who was studied
289 randomized participants with an on-treatment assessment, from 365 enrolled outpatients.
What was found
The patch had a modest advantage on some depression scales; the 17-item Hamilton scale comparison did not reach conventional statistical significance.
What it cannot establish
The measures did not all give the same result. The absence of a blood-pressure difference in this study cannot eliminate interaction risks or override current prescribing precautions.
Read the original studyUse the formulation’s own prescribing information
The cited US label covers the EMSAM patch for adult major depressive disorder. Indication, age restrictions, interacting medicines and food precautions belong to that product’s treatment plan, not to an informal nootropic category.
Supporting sourceSources
2002 randomized transdermal trial
2003 randomized transdermal trial
US EMSAM prescribing information
Sources checked 2026-10-01.
General education; not a personal treatment plan.